SHARE

Researchstore.biz launched a study titled “Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market by Procedure (Transapical, Transfemoral, Transaortic), Region (North America, Europe, Asia Pacific, South America and the Middle East and Africa)” and Global Forecast 2018-2025.

The global transcatheter aortic valve replacement/implantation (TAVR/TAVI) market is expected to grow from USD 3.67 Billion in 2017 to USD 6.86 Billion by 2025 at a CAGR of 7.11% during the forecast period from 2018-2025. Major drivers that fuel the growth of transcatheter aortic valve replacement/implantation (TAVR/TAVI) market are:

  • Increasing prevalence of severe aortic stenosis and asymptomatic
  • Advancements in the transcatheter aortic valves and increase in adoption rate of TAVI devices
  • Increasing incidence of cardiovascular diseases
  • Increasing demand for minimally invasive surgeries

Market Summary:

The transcatheter aortic valve replacement/implantation (TAVI/TAVR) are the process used to implement and replace aortic valve. It is the viable option in contrast to cumbersome open heart medical procedure particularly for high risk patients. The system decreases serious degenerative aortic stenosis and expands survival rate of patients. TAVR is executed to treat high-risk patients suffering from aortic stenosis and also involves implantation of transcatheter aortic valves to redevelop the blood circulation ability of the aortic valve. The TAVI valve is fixed within the contaminated aortic valve.

DOWNLOAD FREE SAMPLE REPORT:https://researchstore.biz/report/global-transcatheter-aortic-valve-replacement-implantation-tavr-tavi-market/71603/#requestforsample

Increasing prevalence of severe aortic stenosis and asymptomatic and increasing incidence of cardiovascular diseases to drive transcatheter aortic valve replacement/implantation (TAVR/TAVI) market:

Increasing demand for minimally invasive surgeries, increasing prevalence of severe aortic stenosis and asymptomatic and increasing incidence of cardiovascular diseases are the key driving factors for the transcatheter aortic valve replacement/implantation (TAVR/TAVI) market. The stringent government regulations for approval of transcatheter aortic valves and high cost associated with TAVI may limit the growth of market. However, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies is expected to boost the transcatheter aortic valve replacement/implantation (TAVR/TAVI) market over the forecast period.

Segmentation Analysis:

The global transcatheter aortic valve replacement/implantation (TAVR/TAVI) market is segmented on the basis of procedure and regions.

Transfemoral segment valued around USD 1.33 Billion in 2017

Procedure segment includes transapical, transfemoral, and transaortic. The transfemoral segment is anticipated to grow with the highest CAGR over the forecast period. The acceptance by a majority of doctors due to its positive outcomes of TAVR/TAVI and rise in prevalence of aortic stenosis coupled with an increase in geriatric population are the key factors to drive the demand of the transfemoral segment

Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and the Middle East and Africa. North America held the largest market share of approximately 31.11% in 2017. The high adoption of technologically advanced products is the major factor that led to the growth of transcatheter aortic valve replacement/implantation (TAVR/TAVI) market in this region.

ACCESS FULL REPORT:https://researchstore.biz/report/global-transcatheter-aortic-valve-replacement-implantation-tavr-tavi-market/71603/

Competitive Analysis:

The major players for transcatheter aortic valve replacement/implantation (TAVR/TAVI) market include Abbott Laboratories, Boston Scientific Corporation, JC Medical, Inc., Medtronic plc., NVT AG, Bracco S.p.A., Edwards Lifesciences Corporation, JenaValve Technology, Inc., Meril Life Sciences Pvt. Ltd., Transcatheter Technologies GmbH, SYMETIS, Braile Biomedica, Venus Medtech, Inc., and others.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs.